{"id":599898,"date":"2026-06-19T10:42:42","date_gmt":"2026-06-19T10:42:42","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/599898\/growth-hormone-deficiency-market-size-expected-to-witness-significant-growth-by-2034-estimates-delveinsight.html"},"modified":"2026-06-19T10:42:42","modified_gmt":"2026-06-19T10:42:42","slug":"growth-hormone-deficiency-market-size-expected-to-witness-significant-growth-by-2034-estimates-delveinsight","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/599898\/growth-hormone-deficiency-market-size-expected-to-witness-significant-growth-by-2034-estimates-delveinsight.html","title":{"rendered":"Growth Hormone Deficiency Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight"},"content":{"rendered":"<div style=\"font-style:italic;padding:8px 0px\">Emerging Growth Hormone Deficiency therapies including LUM-201 (ibutamoren) and SCO-240, alongside marketed long-acting options like SOGROYA, SKYTROFA\/TRANSCON hGH, and NGENLA, are driving market growth.<\/div>\n<p style=\"text-align: justify\">DelveInsight&#8217;s &#8220;Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2034&#8221; report delivers an in-depth understanding of Growth Hormone Deficiency, historical and forecasted epidemiology, as well as the Growth Hormone Deficiency market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify\">Discover Key Insights into the Growth Hormone Deficiency Market with DelveInsight&#8217;s In-Depth Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/growth-hormone-deficiency-ghd-market?utm_source=abnewswire&amp;utm_medium=pr&amp;utm_campaign=kkpr\">Growth Hormone Deficiency Market Size<\/a><\/p>\n<p style=\"text-align: justify\">Key Takeaways from the Growth Hormone Deficiency Market Report<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The Growth Hormone Deficiency market size in the 7MM is expected to grow from USD 1,626 million in 2025 to USD 3,304 million in 2034, registering a CAGR of 5.7%.<\/p>\n<\/li>\n<li>\n<p>The leading Growth Hormone Deficiency companies include Novo Nordisk, Ascendis Pharma, Pfizer\/OPKO Health, JCR Pharmaceuticals, Eli Lilly, Lumos Pharma, SCOHIA PHARMA, and others.<\/p>\n<\/li>\n<li>\n<p>Rising prevalence of Growth Hormone Deficiency, fueled by improved diagnostics, higher survival rates of premature infants, increased pituitary disorders, and environmental factors such as endocrine-disrupting chemicals, is accelerating demand for growth hormone replacement therapies.<\/p>\n<\/li>\n<li>\n<p>Innovation in long-acting GH analogs, sustained-release systems, and oral GH secretagogue\/SSTR5-antagonist mechanisms is expanding therapeutic options and improving patient adherence.<\/p>\n<\/li>\n<li>\n<p>DelveInsight estimates approximately 206,000 total prevalent cases of Growth Hormone Deficiency across the 7MM in 2023, of which around 165,000 were diagnosed.<\/p>\n<\/li>\n<li>\n<p>The United States accounted for the largest share of diagnosed prevalent cases (42.5%), followed by EU4 and the UK (41.7%) and Japan (15.8%) in 2023.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Stay ahead in the Growth Hormone Deficiency Market with DelveInsight&#8217;s Strategic Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/growth-hormone-deficiency-ghd-market?utm_source=abnewswire&amp;utm_medium=pr&amp;utm_campaign=kkpr\">Growth Hormone Deficiency Market Outlook<\/a><\/p>\n<p style=\"text-align: justify\">Growth Hormone Deficiency Epidemiology Segmentation in the 7MM<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Prevalent Cases of Growth Hormone Deficiency<\/p>\n<\/li>\n<li>\n<p>Total Diagnosed Prevalent Cases of Growth Hormone Deficiency<\/p>\n<\/li>\n<li>\n<p>Total Diagnosed Prevalent Cases of Pediatric Growth Hormone Deficiency<\/p>\n<\/li>\n<li>\n<p>Total Diagnosed Prevalent Cases of Adult Growth Hormone Deficiency<\/p>\n<\/li>\n<li>\n<p>Gender-specific Cases of Growth Hormone Deficiency<\/p>\n<\/li>\n<li>\n<p>Etiology-specific Cases of Growth Hormone Deficiency<\/p>\n<\/li>\n<li>\n<p>Total Growth Hormone Deficiency Market Size<\/p>\n<\/li>\n<li>\n<p>Market Size by Therapies Market Size by Geography<\/p>\n<\/li>\n<li>\n<p>Growth Hormone Deficiency Treatment Market<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Growth Hormone Deficiency Pipeline Analysis<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>SOGROYA (somapacitan-beco): Novo Nordisk SOGROYA is a human growth hormone analog engineered for once-weekly administration. It binds to a dimeric GH receptor, triggering intracellular signaling with effects mediated both directly and through liver-produced IGF-1. It is approved for pediatric patients aged 2.5 years and older with growth failure due to inadequate endogenous GH secretion, as well as for adults requiring GH replacement therapy. Approvals span the US FDA (adult GHD, August 2020; pediatric GHD, April 2023), the EMA (March 2021), and Japan&#8217;s PMDA (adult GHD, January 2021; pediatric short stature, June 2023).<\/p>\n<\/li>\n<li>\n<p>SKYTROFA \/ TRANSCON hGH (lonapegsomatropin-tcgd): Ascendis Pharma SKYTROFA is a pegylated human growth hormone administered via once-weekly subcutaneous injection. It acts as a prodrug, gradually releasing unmodified somatropin, which binds GH receptors to drive both direct tissue\/metabolic effects and IGF-1-mediated actions supporting skeletal growth. The US FDA approved SKYTROFA in August 2021 for pediatric patients aged 1 year and older (weighing at least 11.5 kg) with growth failure from inadequate endogenous GH secretion; the EC granted authorization in January 2022 for children and adolescents aged 3-18 years. It is also under evaluation in a global Phase III trial for adult Growth Hormone Deficiency and in Japan for pediatric Growth Hormone Deficiency.<\/p>\n<\/li>\n<li>\n<p>LUM-201 (ibutamoren): Double Point Ventures (Lumos Pharma) LUM-201 is an investigational, orally administered, once-daily small molecule that acts as a potent agonist of the Growth Hormone secretagogue receptor, amplifying endogenous pulsatile GH secretion to mirror the body&#8217;s natural release pattern. It holds orphan drug designation in both the US and EU and is currently in Phase II development, with FDA guidance received in May 2024 indicating that a placebo-controlled Phase III trial would be acceptable.<\/p>\n<\/li>\n<li>\n<p>SCO-240: SCOHIA PHARMA SCO-240 is an orally available, selective antagonist of Somatostatin Receptor 5 (SSTR5). In a Phase I trial, it elicited robust GH secretion without affecting other pituitary hormones, providing first clinical evidence supporting SSTR5 antagonism as a viable approach for stimulating GH release in growth hormone-related disorders.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Growth Hormone Deficiency Market Insights<\/p>\n<p style=\"text-align: justify\">The current treatment landscape is anchored by recombinant human growth hormone (somatropin), with both traditional daily-injection formulations and newer long-acting, once-weekly analogs available.<\/p>\n<p style=\"text-align: justify\">Long-acting GH analogs achieve extended activity through distinct modifications: SOGROYA uses an albumin-binding moiety, SKYTROFA is a transient PEGylated prodrug, and NGENLA fuses GH with a C-terminal peptide derived from human chorionic gonadotropin.<\/p>\n<p style=\"text-align: justify\">The competitive landscape is innovation-driven, with companies such as Novo Nordisk, Ascendis Pharma, Pfizer\/OPKO Health, Eli Lilly, Lumos Pharma, and SCOHIA PHARMA progressing assets through clinical development, spanning long-acting injectables to oral mimetics.<\/p>\n<p style=\"text-align: justify\">Convenience and reduced injection burden are emerging as key competitive differentiators, particularly for improving adherence among pediatric patients and increasing recognition of underdiagnosed adult cases.<\/p>\n<p style=\"text-align: justify\">Get In-Depth Knowledge on Growth Hormone Deficiency Market Trends and Forecasts with DelveInsight @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/growth-hormone-deficiency-ghd-market?utm_source=abnewswire&amp;utm_medium=pr&amp;utm_campaign=kkpr\"> https:\/\/www.delveinsight.com\/report-store\/growth-hormone-deficiency-ghd-market<\/a><\/p>\n<p style=\"text-align: justify\">Growth Hormone Deficiency Market Outlook<\/p>\n<p style=\"text-align: justify\">Growth Hormone Deficiency results from inadequate GH production by the anterior pituitary gland, with origins classified as congenital, acquired, or idiopathic. The total 7MM market size was approximately USD 1,380.5 million in 2023, with the United States contributing approximately USD 873.4 million and serving as the largest single market. EU4 and the UK collectively accounted for around USD 370.2 million (roughly 27% of total 7MM revenue), led by Germany (~USD 96.5 million), the UK (~USD 86.2 million), and France (~USD 82.0 million), while Japan recorded approximately USD 137.0 million. Market growth through 2034 is expected to be driven by the launch of oral and long-acting emerging therapies, with LUM-201 alone projected to generate approximately USD 131.1 million across the 7MM by 2034. Growth may be tempered by diagnostic challenges, underdiagnosis in adults, pricing and reimbursement hurdles, and a continued reliance on daily-injection regimens that affect long-term adherence.<\/p>\n<p style=\"text-align: justify\">Scope of the Growth Hormone Deficiency Market Report<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Coverage: 7MM<\/p>\n<\/li>\n<li>\n<p>Study Period: 2020-2034<\/p>\n<\/li>\n<li>\n<p>Forecast Period: 2025-2034<\/p>\n<\/li>\n<li>\n<p>Growth Hormone Deficiency Companies: Novo Nordisk, Ascendis Pharma, Pfizer\/OPKO Health, JCR Pharmaceuticals, Eli Lilly, Lumos Pharma, SCOHIA PHARMA, and others<\/p>\n<\/li>\n<li>\n<p>Growth Hormone Deficiency Therapies: SOGROYA, SKYTROFA\/TRANSCON hGH, NGENLA, GROWJECT, LUM-201, SCO-240, and others<\/p>\n<\/li>\n<li>\n<p>Growth Hormone Deficiency Market Access &amp; Reimbursements, Unmet Needs and Perspectives<\/p>\n<\/li>\n<li>\n<p>Growth Hormone Deficiency SWOT Analysis and KOL Views<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Unlock Strategic Insights with DelveInsight&#8217;s Comprehensive Growth Hormone Deficiency Market Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/growth-hormone-deficiency-ghd-market?utm_source=abnewswire&amp;utm_medium=pr&amp;utm_campaign=kkpr\">Growth Hormone Deficiency Market Drivers and Barriers<\/a><\/p>\n<p style=\"text-align: justify\">Table of Contents<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Key Insights<\/p>\n<\/li>\n<li>\n<p>Report Introduction<\/p>\n<\/li>\n<li>\n<p>GHD Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Key Events<\/p>\n<\/li>\n<li>\n<p>Disease Background and Overview<\/p>\n<\/li>\n<li>\n<p>Methodology<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population<\/p>\n<\/li>\n<li>\n<p>Patient Journey<\/p>\n<\/li>\n<li>\n<p>Marketed Drugs<\/p>\n<\/li>\n<li>\n<p>Emerging Drugs<\/p>\n<\/li>\n<li>\n<p>GHD &ndash; 7MM Market Analysis<\/p>\n<\/li>\n<li>\n<p>Key Opinion Leaders&rsquo; Views<\/p>\n<\/li>\n<li>\n<p>Unmet Needs<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis<\/p>\n<\/li>\n<li>\n<p>Market Access and Reimbursement<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Related Reports<\/p>\n<p style=\"text-align: justify\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/growth-hormone-deficiency-ghd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pr&amp;utm_campaign=kkpr\">Growth Hormone Deficiency (GHD) Pipeline Insight, 2026<\/a><\/p>\n<p style=\"text-align: justify\">&#8220;Growth Hormone Deficiency (GHD) Pipeline Insight, 2026&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Growth Hormone Deficiency (GHD) market. A detailed picture of the Growth Hormone Deficiency (GHD) pipeline landscape is provided, which includes the disease overview and Growth Hormone Deficiency (GHD) treatment guidelines. The assessment part of the report embraces in-depth Growth Hormone Deficiency (GHD) commercial assessment and clinical assessment of the Growth Hormone Deficiency (GHD) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Growth Hormone Deficiency (GHD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/growth-hormone-deficiency-ghd-epidemiology-forecast?utm_source=abnewswire&amp;utm_medium=pr&amp;utm_campaign=kkpr\">Growth Hormone Deficiency (GHD) Epidemiology Forecast &#8211; 2034<\/a><\/p>\n<p style=\"text-align: justify\">DelveInsight&rsquo;s &ldquo;Growth Hormone Deficiency Epidemiology Forecast &ndash; 2034&rdquo; report delivers an in-depth understanding of GHD, historical and forecasted epidemiology of GHD in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify\">About Us<\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kanishk Kumar<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=growth-hormone-deficiency-market-size-expected-to-witness-significant-growth-by-2034-estimates-delveinsight\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/growth-hormone-deficiency-ghd-market\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/growth-hormone-deficiency-ghd-market<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=growth-hormone-deficiency-market-size-expected-to-witness-significant-growth-by-2034-estimates-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Emerging Growth Hormone Deficiency therapies including LUM-201 (ibutamoren) and SCO-240, alongside marketed long-acting options like SOGROYA, SKYTROFA\/TRANSCON hGH, and NGENLA, are driving market growth. DelveInsight&#8217;s &#8220;Growth Hormone Deficiency Market Insights,<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/599898"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=599898"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/599898\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=599898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=599898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=599898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}